香港联交所最新资料显示，11月24日，主席兼执行董事蔡东晨增持石药集团(01093)1486.6万股，每股作 价7.4608港元，总金额约为1.11亿港元。增持后最新持股数目约为28.87亿股，最新持股比例为25.06%。 ...

智通财经APP获悉，香港联交所最新资料显示，11月24日，主席兼执行董事蔡东晨增持石药集团 (01093)1486.6万股，每股作价7.4608港元，总金额约为1.11亿港元。增持后最新持股数目约为28.87亿 股，最新持股比例为25.06%。 ...

石药集团(01093)发布公告，集团自主研发的化学1类新药双链小干扰RNA药物(SYH2061注射液)已获得 美国食品药品监督管理局(FDA)批准，可在美国开展临床试验。该产品亦已于2025年10月获得中华人民 共和国国家药品监督管理局批准在中国开展临床试验。 临床前研究显示，该产品在药物活性和药效持续性方面均优于同类型siRNA产品，展现出药物作用效果 持久、安全性良好、患者依从性高等差异化优势，具有较高的临床开发价值。 该产品是一款通过偶联乙醯半乳糖胺(GalNAc)实现肝脏靶向递送的siRNA药物，以皮下给药的方式靶向 补体蛋白C5，能有效降低C5水平。通过优化序列和化学修饰的策略，该产品可实现更持久的基因沉默 效果，是国内自主研发并进入临床试验阶段的首款超长效降低C5水平的siRNA药物，适用于治疗IgA肾 病及其他补体介导相关性疾病。 ...

Core Viewpoint - The company, Stone Pharmaceutical Group, has received FDA approval for its self-developed chemical class 1 new drug, SYH2061 injection, which is set to enter clinical trials in the United States. The drug has also been approved by the National Medical Products Administration of China for clinical trials starting in October 2025 [1]. Group 1 - The drug is a siRNA medication that utilizes GalNAc for targeted delivery to the liver, aiming to reduce complement protein C5 levels effectively [1]. - SYH2061 is the first domestically developed ultra-long-acting siRNA drug targeting C5 to enter clinical trials, indicating significant progress in the treatment of IgA nephropathy and other complement-mediated diseases [1]. - Preclinical studies demonstrate that SYH2061 outperforms similar siRNA products in terms of drug activity and efficacy duration, showcasing its long-lasting effects, good safety profile, and high patient compliance [1].

Core Viewpoint - The company, Stone Pharmaceutical Group, has received FDA approval for its self-developed siRNA drug SYH2061 injection, allowing clinical trials in the U.S. This drug is also approved for clinical trials in China starting October 2025 [1] Group 1: Product Details - SYH2061 is a first-in-class siRNA drug that targets complement protein C5 through GalNAc conjugation for liver-targeted delivery [1] - The drug is administered subcutaneously and is designed to effectively lower C5 levels, making it suitable for treating IgA nephropathy and other complement-mediated diseases [1] Group 2: Clinical Development - This product is the first domestically developed siRNA drug to enter clinical trials in China with a long-lasting effect on reducing C5 levels [1] - Preclinical studies indicate that SYH2061 outperforms similar siRNA products in terms of drug activity and duration of effect, showcasing its potential clinical development value [1]

Core Viewpoint - Eli Lilly has achieved a market capitalization exceeding $1 trillion, driven by the strong performance of its flagship product, tirzepatide, amidst challenges such as patent expirations, increasing market competition, and pricing pressures [1][2][4]. Financial Performance - Eli Lilly's Q3 revenue reached $17.6 billion, a 54% year-over-year increase, with tirzepatide's sales contributing significantly [1]. - Tirzepatide's diabetes version, Mounjaro, generated $6.515 billion in Q3 sales, while the weight loss version, Zepbound, achieved $3.588 billion [1]. - Combined, these products accounted for $10.103 billion in Q3 sales and $24.837 billion year-to-date, representing 49% of Eli Lilly's total revenue, with a 125% year-over-year growth [2]. Market Position and Competition - Eli Lilly's market share for its products among new patients in the U.S. has risen to 70%-75% [4]. - Tirzepatide has surpassed its competitor, semaglutide, in prescription volume, holding a 57.9% share compared to semaglutide's 41.7% as of Q3 2025 [4]. Industry Dynamics - The GLP-1 drug class is expected to become one of the largest pharmaceutical categories globally within the next three to five years [2]. - The market for obesity and metabolic drugs is projected to exceed $100 billion by 2030, with GLP-1 drugs being a key driver [6]. Competitive Landscape - Novo Nordisk remains a dominant player in the weight loss drug market, with its GLP-1 products generating significant revenue [5][6]. - Eli Lilly faces increasing competition from various domestic pharmaceutical companies developing next-generation GLP-1 drugs [7][8]. Challenges Ahead - Eli Lilly's reliance on a single product, patent expiration risks, and intensifying competition are significant concerns [9]. - Pricing pressures are mounting, with agreements to lower drug prices starting in 2026, which may impact Eli Lilly's market revenue [8]. Strategic Initiatives - To address these challenges, Eli Lilly is pursuing external acquisitions and technological advancements to create new growth avenues [10]. - The company has made significant investments in gene therapy and AI drug development, including partnerships and acquisitions aimed at expanding its portfolio [10][11]. Future Outlook - Eli Lilly's leadership emphasizes the importance of data-driven decision-making in navigating future challenges and opportunities [11]. - The company must explore new growth paths beyond GLP-1 drugs to sustain its market position and develop the next milestone product following tirzepatide [11].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 （股份代號：1093） （於香港註冊成立之有限公司） 自願公告 雙鏈小干擾RNA藥物（SYH2061注射液） 在美國獲臨床試驗批准 石 藥 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）董 事 會（「 董 事 會 」）欣 然 宣 布，本集團自主研發的化學1類新藥雙鏈小干擾RNA（「si RNA」）藥物（ SYH2061注射液 ）（「該 產 品」）已獲 得 美國 食 品 藥品 監 督管 理 局 (FDA) 批 准 ，可 在 美 國開 展 臨床 試 驗。 該 產 品亦 已 於2025年10月獲得中華人民共和國國家藥品監督管理局批准在中國開展臨床試驗。 該產品是一款通過偶聯乙醯半乳糖胺(Gal NAc)實現肝臟靶向遞送的si RNA 藥物，以皮下給 藥的方式 ...

Core Insights - Eli Lilly has achieved a market capitalization exceeding $1 trillion, marking a record in the pharmaceutical industry, driven by the strong performance of its flagship product, tirzepatide [2][4] - The sales of tirzepatide's diabetes version, Mounjaro, reached $6.515 billion in Q3, contributing significantly to Eli Lilly's overall revenue growth [2] - The GLP-1 drug class is expected to become one of the largest pharmaceutical categories globally in the next three to five years, highlighting the transformative impact of a single blockbuster drug [3] Financial Performance - Eli Lilly's Q3 revenue reached $17.6 billion, a 54% year-over-year increase, with tirzepatide products generating a combined sales of $10.103 billion in Q3 alone [2] - The total sales for tirzepatide in the first three quarters amounted to $24.837 billion, accounting for 49% of Eli Lilly's total revenue, with a year-over-year growth of 125% [2] Market Dynamics - Eli Lilly's market share among new patients in the U.S. has risen to between 70% and 75%, indicating strong competitive positioning [4] - The prescription volume for tirzepatide has surpassed that of its main competitor, semaglutide, with a market share of 57.9% compared to 41.7% for semaglutide as of Q3 2025 [4] Competitive Landscape - Novo Nordisk remains a dominant player in the weight loss drug market, with its GLP-1 products generating significant revenue, including $32.4 billion from diabetes and obesity care in the first three quarters of 2025 [5] - The GLP-1 drug class is projected to exceed $100 billion in market size by 2030, with Eli Lilly and Novo Nordisk leading the charge [6] Challenges and Strategic Moves - Eli Lilly faces challenges such as reliance on a single product, patent expiration risks, and increasing competition in the GLP-1 market [9] - The company is pursuing external acquisitions and advanced technology investments to diversify its growth avenues, including strategic alliances in gene therapy and AI drug development [9][10] - Price pressures are mounting as Eli Lilly and Novo Nordisk have agreed to lower prices for obesity treatment drugs starting in 2026, which may impact short-term revenue [8]

Core Insights - Eli Lilly has achieved a market capitalization exceeding $1 trillion, becoming the first pharmaceutical company to reach this milestone, driven by the strong performance of its flagship product, tirzepatide [2][4] - The sales of tirzepatide's diabetes version, Mounjaro, reached $6.515 billion in Q3, contributing significantly to Eli Lilly's overall revenue growth [2] - The competitive landscape for GLP-1 drugs is intensifying, with Eli Lilly facing challenges from patent expirations, market competition, and pricing pressures [2][8] Financial Performance - Eli Lilly's Q3 revenue reached $17.6 billion, a 54% year-over-year increase, with tirzepatide accounting for 49% of total revenue [2] - The combined sales of tirzepatide's two versions in Q3 amounted to $10.103 billion, with a total of $24.837 billion for the first three quarters, indicating a 125% year-over-year growth [2] Market Dynamics - The GLP-1 drug class is expected to become one of the largest pharmaceutical categories globally within the next three to five years, highlighting the potential for significant market growth [3][6] - Eli Lilly's market share among new patients in the U.S. has risen to between 70% and 75%, surpassing its main competitor, semaglutide [4] Competitive Landscape - Novo Nordisk remains a strong competitor in the weight loss drug market, with its product semaglutide generating substantial revenue [5] - The GLP-1 market is characterized by a "dual oligopoly" competition, with many domestic pharmaceutical companies actively developing next-generation GLP-1 drugs [6][7] Strategic Initiatives - Eli Lilly is pursuing aggressive acquisition strategies and business development plans to expand its market presence and explore new growth avenues [10] - The company has made significant investments in gene therapy and AI drug development, indicating a strategic shift towards innovative treatment options [10] Challenges Ahead - Despite current success, Eli Lilly faces significant challenges, including reliance on a single product, patent expiration risks, and increasing competition [9] - The company must accelerate efforts to diversify its product portfolio and develop new growth drivers to sustain its market position [9][10]

Group 1: Policy Insights - The speech by the General Secretary on November 21 emphasized the importance of reform and innovation, stating that rural reform should learn from past mistakes and promote openness[1] - The focus on maintaining reasonable investment growth and improving investment efficiency was highlighted during recent inspections in Shandong and Hebei[2] - The State-owned Assets Supervision and Administration Commission (SASAC) held a meeting on November 21, resulting in the signing of key projects involving 17 units in critical sectors such as new materials and artificial intelligence[12] Group 2: Economic Development Strategies - The need for a comprehensive legal and policy framework to guide outward-oriented enterprises was stressed during inspections in Hubei and Hunan[2] - The importance of enhancing traditional industries and nurturing emerging sectors was reiterated, with a focus on optimizing government investment[9] - The launch of commercial trials for satellite IoT services was announced at the 2025 China 5G+ Industrial Internet Conference, indicating a push towards advanced technology integration[13]